Research

Our research focuses on:

  • Detection, staging and treatment monitoring of cancer with PET/CT (personalized cancer treatment)
  • Peptide-based molecular imaging probes for biological characterization and treatment of tumors
  • Biological imaging for radiation treatment planning
  • Molecular neuro-imaging in movement disorders and dementia
  • New detector systems, reconstruction algorithms and quantification methods for PET and SPECT

Senior Scientists:

  • Prof. Wolfgang A. Weber, MD
    (department chair; board-certified nuclear medicine physician; focus on oncology)
  • Philipp T. Meyer, MD, PhD
    (vice-chair; board-certified nuclear medicine physician; focus on neurology)
  • Christof Rottenburger, MD
    (attending physician; board-certified nuclear medicine physician; focus neurooncology)
  • Damian Wild, MD
    (attending physician; board-certified nuclear medicine physician; focus neuroendocrine tumors and radionuclide therapy)
  • Martin Béhé, PhD
    (chief radiochemist; focus on peptide radiochemistry)
  • Prof. Helmut Maecke, PhD
    (radiochemist; focus on peptide radiochemistry)
  • Michael Mix, PhD
    (chief physicist, focus on scanner development and image reconstruction)

Selection of recent publications:

  1. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA.
    Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.
    Cancer Res. 2009;69:3173-9.
  2. Wild D, Mäcke H, Christ E, Gloor B, Reubi JC.
    Glucagon-like peptide 1-receptor scans to localize occult insulinomas.
    N Engl J Med. 2008;359:766-8.
  3. Weber WA, Grosu AL, Czernin J.
    Technology Insight: advances in molecular imaging and an appraisal of PET/CT scanning.
    Nat Clin Pract Oncol. 2008;5:160-70.
  4. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang X, Erchegyi J, Rivier J, Mäcke HR, Reubi JC.
    Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors.
    Proc Natl Acad Sci U S A. 2006;103:16436-41.
  5. Meyer PT, Sattler B, Winz OH, Fundke R, Oehlwein C, Kendziorra K, Hesse S, Schaefer WM, Sabri O.
    Kinetic analyses of [123I]IBZM SPECT for quantification of striatal dopamine D2 receptor binding: a critical evaluation of the single-scan approach.
    Neuroimage. 2008;42:548-58.

For full list of publications see: www.pubmed.org (enter Name Initial of scientist of interest, e.g. “Weber WA”).

Scroll to the top